- Home
- ACET vs QNCX Comparison
ACET vs QNCX Comparison
Compare ACET & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- QNCX
- Stock Information
- Founded
- ACET 1947
- QNCX 2012
- Country
- ACET United States
- QNCX United States
- Employees
- ACET N/A
- QNCX N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACET Health Care
- QNCX Health Care
- Exchange
- ACET Nasdaq
- QNCX Nasdaq
- Market Cap
- ACET 44.4M
- QNCX 44.0M
- IPO Year
- ACET N/A
- QNCX 2019
- Fundamental
- Price
- ACET $0.60
- QNCX $1.03
- Analyst Decision
- ACET Buy
- QNCX Strong Buy
- Analyst Count
- ACET 6
- QNCX 5
- Target Price
- ACET $6.00
- QNCX $8.00
- AVG Volume (30 Days)
- ACET 523.1K
- QNCX 128.6K
- Earning Date
- ACET 05-13-2025
- QNCX 05-12-2025
- Dividend Yield
- ACET N/A
- QNCX N/A
- EPS Growth
- ACET N/A
- QNCX N/A
- EPS
- ACET N/A
- QNCX N/A
- Revenue
- ACET N/A
- QNCX N/A
- Revenue This Year
- ACET N/A
- QNCX N/A
- Revenue Next Year
- ACET N/A
- QNCX N/A
- P/E Ratio
- ACET N/A
- QNCX N/A
- Revenue Growth
- ACET N/A
- QNCX N/A
- 52 Week Low
- ACET $0.45
- QNCX $0.51
- 52 Week High
- ACET $2.08
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- ACET 43.47
- QNCX 32.65
- Support Level
- ACET $0.51
- QNCX $0.98
- Resistance Level
- ACET $0.61
- QNCX $1.10
- Average True Range (ATR)
- ACET 0.07
- QNCX 0.10
- MACD
- ACET 0.01
- QNCX -0.00
- Stochastic Oscillator
- ACET 55.54
- QNCX 22.94
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.